{
    "symbol": "RIGL",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 19:25:39",
    "content": " Regarding olutasidenib, we are thrilled with the longer term data from the interim analysis of the registrational Phase 2 cohort of patients with relapsed refractory AML that demonstrates the differentiation of our potential market leading therapy. Please proceed with your questions. Please proceed with your questions. Please proceed with your questions. That said, with continued, as we think about the top line, you've already described the $20 million of potential cash flow from Kissei upon that approval with TAVALISSE sales growth, which we expect into the future with now olutasidenib revenues with the PDUFA date in February and the launch thereafter, we would expect \u00e2\u0080\u009923 revenues from our olutasidenib sales. Please proceed with your questions. Please proceed with your questions."
}